Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136690 · ClinicalTrials.gov registry record · Phase 1
Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05136690 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 38 participants.
The verdict
NCT05136690, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary purpose of this randomized, double-blind, placebo-controlled cross-over study was to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC) and participants with mild-to-moderate schizophrenia (SZ) to determine if the mean inter-trial coherence (ITC) magnitude derived from the 40 Hz-ASSR is lower in SZ than in HC at baseline.
Interventions
- DRUG Nicotine patch
- DRUG Placebo capsule
- DRUG Placebo patch
- DRUG MK-4334
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2022-11-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05136690
The ClinicalTrials.gov registry entry for NCT05136690 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nicotine patch is the first listed.
NCT05136690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05136690 about?
NCT05136690 is a clinical study titled "Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)". The primary purpose of this randomized, double-blind, placebo-controlled cross-over study was to record and measure 40 Hz-auditory steady-state response (ASSR) in healthy controls (HC) and participants with mild-to-moderate schizophrenia (SZ) to determine if the mean inter-trial coherence (ITC) magn...
What is the current status of trial NCT05136690?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-04-27. Estimated completion is 2022-11-04.
What interventions are being tested in trial NCT05136690?
The interventions under investigation include: Nicotine patch (DRUG), Placebo capsule (DRUG), Placebo patch (DRUG), MK-4334 (DRUG).
Who is sponsoring clinical trial NCT05136690?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.